Trial site
Instituto Argentino de Diagnostico y Tratamiento IADT
Buenos Aires, C1122AAL, ArgentinaNot linked to an institution yet
- 6running trials
- 1closed trial
The trials here
What the 7 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 2/32 trials
- Status
- Recruiting4 trials
- Active, not recruiting2 trials
- Completed1 trial
- Lead sponsor
- Amgen2 trials
- Pfizer2 trials
- BioNTech SE1 trial
- Bristol-Myers Squibb1 trial
- Eli Lilly and Company1 trial
Running trials
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Juan Cundom, Site 0345
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Active, not recruiting
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566· Phase 3· Amgen· Source
Active, not recruiting
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error